Review article:: systemic and topical steroids in inflammatory bowel disease

被引:19
|
作者
Schölmerich, J [1 ]
机构
[1] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany
关键词
D O I
10.1111/j.1365-2036.2004.02059.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Steroids are still widely used in the treatment of inflammatory bowel diseases. Pharmacological studies have shown that there is no major abnormality in the pharmacokinetics of steroids in these disorders. Foam preparations with rectal application decrease the bioavailability to low levels, eliminating systemic complications. For oral use, 'nonsystemic' steroids have been developed. In ulcerative colitis. steroids are rarely needed as 5-aminosalicylates are effective in the majority of patients. This is true for rectal application in distal colitis, as well as in more extensive disease. In Crohn's disease, steroids are more often used; however, in population-based studies, less than 50% of patients have been treated with steroids, as there are alternative treatments available for the large group of patients with mild to moderate activity. For those patients needing steroid treatment, budesonide seems to be a good choice in active disease, but has not shown convincing effects in the maintenance of remission over longer periods of time. There is no place for long-term steroid treatment in ulcerative colitis and very little in Crohn's disease - immunosuppression with azathioprine or related drugs is certainly the better alternative.
引用
收藏
页码:66 / 74
页数:9
相关论文
共 50 条
  • [1] Topical Delivery of Steroids in Inflammatory Bowel Disease
    Girlich, C.
    Schoelmerich, J.
    CURRENT DRUG DELIVERY, 2012, 9 (04) : 345 - 349
  • [2] Topical steroids in chronic inflammatory bowel disease
    Fleig, WE
    INTERNIST, 1997, 38 (12): : 1154 - +
  • [3] New data on inflammatory bowel disease treatment with topical steroids
    Lofberg, R
    IBD AND SALICYLATES - 3, 1998, 20 (01): : 179 - 186
  • [4] Review article: bone disease in inflammatory bowel disease
    Schulte, CMS
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 43 - 49
  • [5] Review article: aminosalicylates in inflammatory bowel disease
    Hanauer, SB
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 60 - 65
  • [6] Review article: cytomegalovirus and inflammatory bowel disease
    Sager, K.
    Alam, S.
    Bond, A.
    Chinnappan, L.
    Probert, C. S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (08) : 725 - 733
  • [7] Review Article: The genetics of inflammatory bowel disease
    Ahmad, T
    Satsangi, J
    Mcgovern, D
    Bunce, M
    Jewell, DP
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (06) : 731 - 748
  • [8] Review article: Osteoporosis and inflammatory bowel disease
    Bernstein, CN
    Leslie, WD
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (09) : 941 - 952
  • [9] Review article: inflammatory bowel disease and genetics
    Weersma, R. K.
    Van Dullemen, H. M.
    Van der Steege, G.
    Nolte, I. M.
    Kleibeuker, J. H.
    Dijkstra, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 : 57 - 65
  • [10] Review article: thiopurines in inflammatory bowel disease
    Derijks, L. J. J.
    Gilissen, L. P. L.
    Hooymans, P. M.
    Hommes, D. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) : 715 - 729